Adalimumab therapy is associated with increased faecal short chain fatty acids in hidradenitis suppurativa

Artiene Tatian, Sara Bordbar, Samuel Der Sarkissian, Jane A. Woods, Geoffrey D. Cains, Chun Wie Chong, Eliana Mariño, John W. Frew

Research output: Contribution to journalArticleResearchpeer-review

3 Citations (Scopus)


Altered gut microbiota composition has been observed in individuals with hidradenitis suppurutiva (HS) and many other inflammatory diseases, including obesity, type 1 and type 2 diabetes. Here, we addressed whether adalimumab, a systemic anti-inflammatory therapy, may impact the microbiota biochemical profile, particularly on beneficial metabolites such as short-chain fatty acids (SCFAs). We conducted an observational single-arm pilot trial to assess gut microbiota composition by 16S rRNA gene sequence analysis and to detect metabolite signatures by gas chromatography in stool samples from participants with HS prior to and 12 weeks after commencing adalimumab therapy. HS individuals that better responded to adalimumab treatment showed a shift in the composition and function of the gut microbiota with significantly increased SCFA acetate and propionate compared to age, gender and BMI-matched healthy controls. A positive correlation was observed between propionate with Prevotella sp and Faecalibacterium prausnitsii. Increased SCFAs, changes in gut microbiota composition, function and metabolic profile following 12 weeks of adalimumab suggest that targeting SCFAs may be considered a potential biomarker to be evaluated as a complementary protective factor or as a diagnostically relevant signal in HS.

Original languageEnglish
Pages (from-to)1872-1880
Number of pages9
JournalExperimental Dermatology
Issue number12
Publication statusPublished - Dec 2022


  • adalimumab
  • hidradenitis suppurativa
  • microbiota
  • SCFAs
  • tunnels

Cite this